Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Tenecteplase pour l'accident vasculaire cérébral en fenêtre tardive guidé par le décalage DWI-FLAIR (TRUST-MISMATCH)

5 novembre 2026 mis à jour par: Bo Song, The First Affiliated Hospital of Zhengzhou University

Thrombolyse par Ténectéplase pour l'Accident Vasculaire Cérébral Ischémique Aigu dans la Fenêtre de 4,5 à 9 Heures Guidée par le Désaccord DWI-FLAIR : Un Essai Multicentrique, Prospectif, Randomisé, en Double Aveugle, Contrôlé par Placebo

The goal of this clinical trial is to evaluate the efficacy and safety of tenecteplase administered 4.5-9 hours after stroke onset (defined as the time the patient was first found with symptoms, including wake-up stroke and unwitnessed stroke) in patients with acute ischemic stroke (AIS) guided by DWI-FLAIR mismatch on MRI. The main questions it aims to answer are:

  1. Does tenecteplase improve functional outcomes at 90 days compared with standard treatments in AIS patients administered 4.5-9 hours after stroke onset guided by DWI-FLAIR mismatch?
  2. The safety of tenecteplase thrombolysis for AIS patients in the 4.5-9 hours guided by DWI-FLAIR mismatch.

Researchers will compare tenecteplase to placebo to see if it is effective and safe for these patients.

Participants will be randomly assigned (1:1) immediately after randomization:

  • Tenecteplase group: received tenecteplase, intravenously as a bolus administered over a period of 5 to 10 seconds at a dose of 0.25 mg per kilogram (maximum dose, 25 mg), plus aspirin placebo (300 mg).
  • Control group: aspirin (300 mg) plus tenecteplase placebo. From day 2 to day 90, all patients will be conformed to the 2023 Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke.

Aperçu de l'étude

Description détaillée

Current clinical guidelines recommend intravenous thrombolysis (IVT) for eligible AIS patients within 4.5 hours of symptom onset. However, approximately 67 to 75% of patients present after 4.5 hours after stroke onset or with an unknown time of onset. CT perfusion (CTP) and perfusion-diffusion magnetic resonance imaging (MRI) have demonstrated that potentially viable brain tissue may persist beyond 4.5 hours after stroke onset. Recent trials, such as EXTEND, TRACE III, and the HOPE study, suggest that IVT can improve functional outcomes in AIS patients with salvageable brain tissue identified beyond 4.5 hours and up to 24 hours, using advanced perfusion imaging. Nonetheless, due to the high cost of perfusion software in developing countries, extended-window thrombolysis has not been widely implemented in many stroke centers. Therefore, it is crucial to develop alternative strategies to guide IVT in patients beyond 4.5 hours.

In recent years, the mismatch between a visible acute ischemic lesion on diffusion-weighted imaging (DWI) and the absence of a corresponding hyperintensity on fluid-attenuated inversion recovery (FLAIR) has been recognized as a predictor of symptom onset within 4.5 hours before imaging. The WAKE-UP trial demonstrated that among AIS patients with unknown time of onset (last known well >4.5 hours) and DWI-FLAIR mismatch, IVT administered within 4.5 hours after symptom recognition significantly improved functional outcomes. However, approximately 30% of AIS patients exhibit DWI-FLAIR mismatch between 4.5 and 9 hours after onset. Whether these patients can benefit from thrombolysis remains uncertain.

TRUST-MISMATCH is a multicenter, prospective, randomized, double-blind, placebo-controlled clinical. We want to evaluate the efficacy and safety of tenecteplase administered 4.5-9 hours after stroke onset (defined as the time the patient was first found with symptoms, including wake-up stroke and unwitnessed stroke) in AIS patients guided by DWI-FLAIR mismatch on MRI.

Type d'étude

Interventionnel

Inscription (Estimé)

564

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Henan
      • Zhengzhou, Henan, Chine, 450052
        • Recrutement
        • The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Age ≥ 18 years;

  2. AIS with symptom onset 4.5-9 hours before enrollment, including wake-up stroke and unwitnessed stroke (onset time defined as when symptoms were first noticed);

  3. Imaging criteria:

    1. DWI-FLAIR mismatch: visible lesion on DWI with no marked visible lesion on FLAIR;
    2. DWI infarct core not exceeding one-third of the middle cerebral artery territory, one-half of the anterior cerebral artery territory, or one-half of the posterior cerebral artery territory;
  4. NIHSS score 4-25;

  5. First-ever stroke or previous stroke without significant disability (pre-stroke mRS ≤ 1);

  6. Signed informed consent from the patient or legally authorized representative.

Exclusion Criteria:

  1. Planned endovascular treatment;
  2. Contradictory to MRI examination;
  3. MRI image not qualified for evaluation;
  4. Obvious head injuries or strokes within 3 months;
  5. Subarachnoid or intracranial hemorrhage;
  6. History of intracranial hemorrhage;
  7. Intracranial tumor, arteriovenous malformation or aneurysm;
  8. Intracranial or spinal cord surgery within 3 months;
  9. Active internal hemorrhage;
  10. platelet count of <100000/mm3;
  11. Aortic arch dissection;
  12. Heparin therapy within 24 hours;
  13. Oral warfarin is being taken and INR>1.6 or APTT abnormal;
  14. Oral anticoagulation therapy;
  15. Systolic pressure≥185 mmHg or diastolic pressure≥110 mmHg;
  16. Blood glucose < 50 mg/dl (2.7mmol/L);
  17. Pregnancy;
  18. Neurological deficit after epileptic seizures;
  19. Major surgery within 1 month;
  20. Gastrointestinal or urinary tract hemorrhage within the previous 30 days;
  21. Myocardial infarction within 3 months;
  22. Allergy to study drugs;
  23. Unlikely to adhere to the trial protocol or follow-up;
  24. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study;
  25. Participation in other interventional clinical trials within the previous 3 months.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Tenecteplase group:

Patients will receive tenecteplase, intravenously as a bolus administered over a period of 5 to 10 seconds at a dose of 0.25 mg per kilogram (maximum dose, 25 mg), plus aspirin placebo (300 mg) immediately after randomization.From day 2 to day 90, all patients will be conformed to the 2023 Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke.

TNK-tPA (0.25 mg/kg, to maximum of 25mg)

Asprin (placebo)

TNK-tPA (placebo)

Comparateur actif: Control group

Patients will receive asprin(300mg) plus intravenous TNK(placebo, 0.25mg/kg, a maximum of 25 mg) immediately after randomization. From day 2 to day 90, patients will be conformed to the 2023 Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke.

Asprin (placebo)

TNK-tPA (placebo)

Asprin (300mg)

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Modified Rankin Scale (mRS)
Délai: 90 ± 7 days

Proportion of subjects of excellent outcome defined as mRS (0-1) at 90 ± 7 days.

90 ± 7 days

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Modified Rankin Scale (mRS)
Délai: 90 ± 7 days

Proportion of subjects of excellent outcome defined as mRS (0-2) at 90 ± 7 days.

90 ± 7 days
Modified Rankin Scale (mRS)
Délai: 90 days

Ordinal shift analysis of mRS at 90 days

90 days
National Institutes of Health Stroke Scale (NIHSS)
Délai: 72 hours and 7 ± 1 days (or at discharge)

Proportion of subjects with an improvement in NIHSS score of ≥2 points from baseline.

72 hours and 7 ± 1 days (or at discharge)
National Institutes of Health Stroke Scale (NIHSS)
Délai: 72 hours and 7 ± 1 days (or at discharge)

Proportion of subjects achieving an NIHSS score of ≤1.

72 hours and 7 ± 1 days (or at discharge)
Barthel (BI)
Délai: 90 ± 7 days

Barthel Index score at 90 ± 7 days.

90 ± 7 days
EuroQol 5-Dimension (EQ-5D)
Délai: 90 ± 7 days

Quality of life measured by EQ-5D scale at 90 ± 7 days.

90 ± 7 days
Modified Rankin Scale (mRS)
Délai: 90 ± 7 days
  1. Proportion of subjects of excellent outcome defined as mRS (0-2) at 90 ± 7 days.
  2. Ordinal distribution of mRS at 90 ± 7 days
90 ± 7 days

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Symptomatic intracranial hemorrhage (sICH)
Délai: 36 hours

Proportion of subjects with symptomatic intracranial hemorrhage (sICH) within 36 hours (according to the ECASS III criteria for the primary safety analysis, with SITS-MOST and Heidelberg definitions used for supportive analyses).

36 hours
Death
Délai: 90 days

Overall mortality rate at 90 days.

90 days
Systemic bleeding
Délai: 90 days

Systemic bleeding at 90 days (according to the GUSTO criteria)

90 days
Adverse events (AEs)/ serious adverse events (SAEs)
Délai: 90 ± 7 days

Proportion of patients with adverse events (AEs)/ serious adverse events (SAEs) within 90 ± 7 days.

90 ± 7 days
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
Délai: 90 ± 7 days

Proportion of subjects experiencing MACCE (defined as ischemic stroke, hemorrhagic stroke, transient ischemic attack, myocardial infarction, or vascular death).

90 ± 7 days

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chaise d'étude: Bo Song, MD, Department of Neurology, the First Affiliated Hospital of Zhengzhou University

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

2 novembre 2026

Achèvement primaire (Estimé)

29 février 2028

Achèvement de l'étude (Estimé)

31 octobre 2028

Dates d'inscription aux études

Première soumission

6 avril 2026

Première soumission répondant aux critères de contrôle qualité

17 avril 2026

Première publication (Réel)

20 avril 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

9 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

5 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner